Colorectal Cancer (CRC) Trial.

Phase 2 Interventional Study

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43

RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable,

olorectal Cancer After Progression on Standard of Care (SOC)

This is a Phase II, open label, multicentre, multi-arm, study to evaluate the preliminary efficacy and safety of RXC004 as monotherapy and in combination with nivolumab in patients with Ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, microsatellite stable (MSS), colorectal cancer (CRC), that have progressed following current standard of care treatment.

This is a Phase II, open label, multicentre, multi-arm, study to evaluate the preliminary efficacy and safety of RXC004 as monotherapy and in combination with nivolumab in patients with Ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, microsatellite stable (MSS), colorectal cancer (CRC), that have progressed following current standard of care treatment.

View this trial on clinicaltrials.gov

What is a clinical trial?

A clinical trial is required by the FDA for any new therapy to come to market. It involves recruiting volunteers to help prove the therapy actually works. Every pill that you take or procedure that is performed by physicians has went through a clinical trial